{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:13:59Z","timestamp":1778876039284,"version":"3.51.4"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","award":["7.4602.20"],"award-info":[{"award-number":["7.4602.20"]}],"id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","award":["7.4606.21"],"award-info":[{"award-number":["7.4606.21"]}],"id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","award":["7.4610.22"],"award-info":[{"award-number":["7.4610.22"]}],"id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006673","name":"L\u00e9on Fredericq Foundation","doi-asserted-by":"publisher","award":["LH-2023"],"award-info":[{"award-number":["LH-2023"]}],"id":[{"id":"10.13039\/501100006673","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006673","name":"L\u00e9on Fredericq Foundation","doi-asserted-by":"publisher","award":["RT-2023"],"award-info":[{"award-number":["RT-2023"]}],"id":[{"id":"10.13039\/501100006673","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006673","name":"L\u00e9on Fredericq Foundation","doi-asserted-by":"publisher","award":["AF-2023"],"award-info":[{"award-number":["AF-2023"]}],"id":[{"id":"10.13039\/501100006673","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013845","name":"Fondation contre le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013845","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005627","name":"Universit\u00e9 de Li\u00e8ge","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005627","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.ebiom.2024.105418","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T16:38:16Z","timestamp":1730306296000},"page":"105418","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["The impact of Charcot-Leyden Crystal protein on mesothelioma chemotherapy: targeting eosinophils for enhanced chemosensitivity"],"prefix":"10.1016","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0319-5600","authenticated-orcid":false,"given":"M\u00e9gane","family":"Willems","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malik","family":"Hamaidia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5135-5982","authenticated-orcid":false,"given":"Alexis","family":"Fontaine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e9lanie","family":"Gr\u00e9goire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Halkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lea","family":"Vilanova Ma\u00f1\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roxane","family":"Terres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majeed","family":"Jamakhani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Deshayes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yves","family":"Brostaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Heinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renaud","family":"Louis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Duysinx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Didier","family":"Jean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Wasielewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnaud","family":"Scherpereel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Blanquart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc","family":"Willems","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2024.105418_bib1","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0226-2020","article-title":"Update on biology and management of mesothelioma","volume":"30","author":"Asciak","year":"2021","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.ebiom.2024.105418_bib2","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.21037\/tlcr.2019.11.11","article-title":"Epidemiology of mesothelioma in the 21st century in Europe and the United States, 40 years after restricted\/banned asbestos use","volume":"9","author":"Alpert","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.ebiom.2024.105418_bib3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/PXH.0000000000000002","article-title":"Novel issues in the epidemiology of asbestos-related diseases","volume":"1","author":"Pira","year":"2022","journal-title":"Curr Opin Epidemiol Public Health"},{"key":"10.1016\/j.ebiom.2024.105418_bib4","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ebiom.2024.105418_bib5","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ebiom.2024.105418_bib6","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ebiom.2024.105418_bib7","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.annonc.2021.11.005","article-title":"Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"33","author":"Popat","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ebiom.2024.105418_bib8","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.3390\/ijms19061603","article-title":"Heterogeneity in malignant pleural mesothelioma","volume":"19","author":"Oehl","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ebiom.2024.105418_bib9","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3390\/ijms19041041","article-title":"Heterogeneity in immune cell content in malignant pleural mesothelioma","volume":"19","author":"Minnema-Luiting","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ebiom.2024.105418_bib10","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.3390\/ijms22094391","article-title":"Inhibition of the histone methyltransferase EZH2 enhances protumor monocyte recruitment in human mesothelioma spheroids","volume":"22","author":"Mola","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ebiom.2024.105418_bib11","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.ajpath.2012.12.028","article-title":"New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas","volume":"182","author":"Mossman","year":"2013","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ebiom.2024.105418_bib12","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrc.2017.42","article-title":"Novel insights into mesothelioma biology and implications for therapy","volume":"17","author":"Yap","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ebiom.2024.105418_bib13","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.jtho.2016.06.022","article-title":"Pleural effusions from patients with mesothelioma induce recruitment of monocytes and their differentiation into M2 macrophages","volume":"11","author":"Ch\u00e9n\u00e9","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.ebiom.2024.105418_bib14","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jtho.2016.06.021","article-title":"Pleural effusion of patients with malignant mesothelioma induces macrophage-mediated T cell suppression","volume":"11","author":"Lievense","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.ebiom.2024.105418_bib15","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.1172\/JCI135528","article-title":"Selective SIRP\u03b1 blockade reverses tumor T cell exclusion and overcomes cancer immunotherapy resistance","volume":"130","author":"Gauttier","year":"2020","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ebiom.2024.105418_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.660039","article-title":"Tumor immune microenvironment and genetic alterations in mesothelioma","volume":"11","author":"Hiltbrunner","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ebiom.2024.105418_bib17","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.3390\/cancers14092164","article-title":"HDAC inhibition with valproate improves direct cytotoxicity of monocytes against mesothelioma tumor cells","volume":"14","author":"Hoyos","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ebiom.2024.105418_bib18","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.128474","article-title":"Inhibition of EZH2 methyltransferase decreases immunoediting of mesothelioma cells by autologous macrophages through a PD-1-dependent mechanism","volume":"4","author":"Hamaidia","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.ebiom.2024.105418_bib19","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.3389\/fonc.2019.01366","article-title":"The immune microenvironment in mesothelioma: mechanisms of resistance to immunotherapy","volume":"9","author":"Chu","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.ebiom.2024.105418_bib20","doi-asserted-by":"crossref","first-page":"5664","DOI":"10.3390\/cancers13225664","article-title":"Mesothelioma malignancy and the microenvironment: molecular mechanisms","volume":"13","author":"Cersosimo","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ebiom.2024.105418_bib21","article-title":"Defining and targeting tumor-associated macrophages in malignant mesothelioma","volume":"120","author":"Wu","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ebiom.2024.105418_bib22","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000030711","article-title":"Factors affecting the life expectancy in malignant pleural mesothelioma: our 10 years of studies and experience","volume":"101","author":"Cimen","year":"2022","journal-title":"Medicine"},{"key":"10.1016\/j.ebiom.2024.105418_bib23","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.lungcan.2022.03.014","article-title":"Prognostic impact of inflammation in malignant pleural mesothelioma: a large-scale analysis of consecutive patients","volume":"166","author":"Fournel","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ebiom.2024.105418_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.suronc.2022.101813","article-title":"Prognostic values of preoperative C-reactive protein, albumin, and neutrophil ratios in patients with malignant pleural mesothelioma who underwent extrapleural pneumonectomy","volume":"43","author":"Okita","year":"2022","journal-title":"Surg Oncol"},{"key":"10.1016\/j.ebiom.2024.105418_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1148798","article-title":"Excess of blood eosinophils prior to therapy correlates with worse prognosis in mesothelioma","volume":"14","author":"Willems","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.ebiom.2024.105418_bib26","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1146\/annurev.immunol.24.021605.090720","article-title":"The eosinophil","volume":"24","author":"Rothenberg","year":"2006","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.ebiom.2024.105418_bib27","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/nri.2017.95","article-title":"Functions of tissue-resident eosinophils","volume":"17","author":"Weller","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ebiom.2024.105418_bib28","series-title":"Clinical immunology","first-page":"349","article-title":"Eosinophils and eosinophilia","author":"Kovalszki","year":"2019"},{"key":"10.1016\/j.ebiom.2024.105418_bib29","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41568-020-0283-9","article-title":"A\u00a0new dawn for eosinophils in the tumour microenvironment","volume":"20","author":"Grisaru-Tal","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ebiom.2024.105418_bib30","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.trecan.2016.10.002","article-title":"Emerging roles for eosinophils in the tumor microenvironment","volume":"2","author":"Reichman","year":"2016","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ebiom.2024.105418_bib31","doi-asserted-by":"crossref","first-page":"5066","DOI":"10.3390\/ijms23095066","article-title":"Eosinophils and lung cancer: from bench to bedside","volume":"23","author":"Sibille","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ebiom.2024.105418_bib32","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00262-018-2255-4","article-title":"Opposing roles of eosinophils in cancer","volume":"68","author":"Simon","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ebiom.2024.105418_bib33","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1111\/j.1365-2222.2008.03037.x","article-title":"Immunoregulatory roles of eosinophils: a new look at a familiar cell","volume":"38","author":"Akuthota","year":"2008","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.ebiom.2024.105418_bib34","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.pop.2016.07.010","article-title":"Eosinophilia","volume":"43","author":"Kovalszki","year":"2016","journal-title":"Prim Care Clin Off Pract"},{"key":"10.1016\/j.ebiom.2024.105418_bib35","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jim.2004.05.003","article-title":"The induction of eosinophil peroxidase release: improved methods of measurement and stimulation","volume":"291","author":"Adamko","year":"2004","journal-title":"J\u00a0Immunol Methods"},{"key":"10.1016\/j.ebiom.2024.105418_bib36","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/1878-0261.12651","article-title":"Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival","volume":"14","author":"Quetel","year":"2020","journal-title":"Mol Oncol"},{"key":"10.1016\/j.ebiom.2024.105418_bib37","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-09307-6","article-title":"Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications","volume":"10","author":"Blum","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.ebiom.2024.105418_bib38","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nprot.2008.226","article-title":"Spheroid-based drug screen: considerations and practical approach","volume":"4","author":"Friedrich","year":"2009","journal-title":"Nat Protoc"},{"key":"10.1016\/j.ebiom.2024.105418_bib39","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.ajpath.2010.12.014","article-title":"Identification of novel markers for the diagnosis of malignant pleural mesothelioma","volume":"178","author":"Gueugnon","year":"2011","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ebiom.2024.105418_bib40","doi-asserted-by":"crossref","first-page":"W193","DOI":"10.1093\/nar\/gkm226","article-title":"g:Profiler--a web-based toolset for functional profiling of gene lists from large-scale experiments","volume":"35","author":"Reimand","year":"2007","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ebiom.2024.105418_bib41","article-title":"clusterProfiler 4.0: a universal enrichment tool for interpreting omics data","volume":"2","author":"Wu","year":"2021","journal-title":"Innovation"},{"key":"10.1016\/j.ebiom.2024.105418_bib42","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.3390\/biom12101385","article-title":"Galectin-10 as a potential biomarker for eosinophilic diseases","volume":"12","author":"Tomizawa","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.ebiom.2024.105418_bib43","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1146\/annurev-pathmechdis-012419-032756","article-title":"Contributions of eosinophils to human health and disease","volume":"15","author":"Klion","year":"2020","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.ebiom.2024.105418_bib44","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1038\/onc.2011.485","article-title":"SASP mediates chemoresistance and tumor-initiating-activity of mesothelioma cells","volume":"31","author":"Canino","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.ebiom.2024.105418_bib45","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1080\/15384101.2019.1652047","article-title":"Chemotherapy-induced senescence, an adaptive mechanism driving resistance and tumor heterogeneity","volume":"18","author":"Guillon","year":"2019","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ebiom.2024.105418_bib46","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1183\/09031936.06.00135305","article-title":"Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses","volume":"27","author":"Hegmans","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ebiom.2024.105418_bib47","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/sj.cgt.7700594","article-title":"Regression of AK7 malignant mesothelioma established in immunocompetent mice following intratumoral gene transfer of interferon gamma","volume":"10","author":"Cordier Kellerman","year":"2003","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.ebiom.2024.105418_bib48","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3389\/fmed.2017.00051","article-title":"Understanding interleukin 33 and its roles in eosinophil development","volume":"4","author":"Johnston","year":"2017","journal-title":"Front Med"},{"key":"10.1016\/j.ebiom.2024.105418_bib49","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/j.jtho.2019.03.029","article-title":"Potential diagnostic and prognostic role of microenvironment in malignant pleural mesothelioma","volume":"14","author":"Salaroglio","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.ebiom.2024.105418_bib50","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12890-022-01968-2","article-title":"Lymphocyte predominance in blood, pleural fluid, and tumour stroma; a prognostic marker in pleural mesothelioma","volume":"22","author":"De Fonseka","year":"2022","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.ebiom.2024.105418_bib51","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/s41568-022-00450-9","article-title":"Exploiting senescence for the treatment of cancer","volume":"22","author":"Wang","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ebiom.2024.105418_bib52","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3389\/fonc.2018.00040","article-title":"Live-cell mesothelioma biobank to explore mechanisms of tumor progression","volume":"8","author":"Oehl","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.ebiom.2024.105418_bib53","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ejca.2010.09.044","article-title":"Induction of senescence markers after neo-adjuvant chemotherapy of malignant pleural mesothelioma and association with clinical outcome: an exploratory analysis","volume":"47","author":"Sidi","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ebiom.2024.105418_bib54","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/JLB.3MR0320-319RR","article-title":"The Charcot\u2013Leyden crystal protein revisited\u2014a lysopalmitoylphospholipase and more","volume":"108","author":"Weller","year":"2020","journal-title":"J\u00a0Leukoc Biol"},{"key":"10.1016\/j.ebiom.2024.105418_bib55","doi-asserted-by":"crossref","first-page":"14859","DOI":"10.1074\/jbc.M200221200","article-title":"Charcot-leyden crystal protein (Galectin-10) is not a dual function galectin with lysophospholipase activity but binds a lysophospholipase inhibitor in a novel structural fashion","volume":"277","author":"Ackerman","year":"2002","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.ebiom.2024.105418_bib56","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.3390\/molecules23112931","article-title":"A\u00a0brief history of charcot-leyden crystal protein\/galectin-10 research","volume":"23","author":"Su","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.ebiom.2024.105418_bib57","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11882-019-0875-1","article-title":"Charcot-leyden crystals in eosinophilic inflammation: active cytolysis leads to crystal formation","volume":"19","author":"Ueki","year":"2019","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.ebiom.2024.105418_bib58","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaw4295","article-title":"Protein crystallization promotes type 2 immunity and is reversible by antibody treatment","volume":"364","author":"Persson","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.ebiom.2024.105418_bib59","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1002\/art.41727","article-title":"Eosinophil ETosis\u2013mediated release of galectin-10 in eosinophilic granulomatosis with polyangiitis","volume":"73","author":"Fukuchi","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ebiom.2024.105418_bib60","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1182\/blood-2018-04-842260","article-title":"Charcot-Leyden crystal formation is closely associated with eosinophil extracellular trap cell death","volume":"132","author":"Ueki","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ebiom.2024.105418_bib61","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.lungcan.2019.11.013","article-title":"Detection of TGF-\u03b2 in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma","volume":"139","author":"Stockhammer","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ebiom.2024.105418_bib62","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/bjc.2015.286","article-title":"Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis","volume":"113","author":"Kirschner","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ebiom.2024.105418_bib63","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ebiom.2024.105418_bib64","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.3390\/cancers12061484","article-title":"TGF\u03b1 promotes chemoresistance of malignant pleural mesothelioma","volume":"12","author":"Staumont","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ebiom.2024.105418_bib65","doi-asserted-by":"crossref","first-page":"817","DOI":"10.3390\/cells10040817","article-title":"Regulation of eosinophilia in asthma\u2014new therapeutic approaches for asthma treatment","volume":"10","author":"Cusack","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.ebiom.2024.105418_bib66","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1056\/NEJMoa2012047","article-title":"Anti\u2013Siglec-8 antibody for eosinophilic gastritis and duodenitis","volume":"383","author":"Dellon","year":"2020","journal-title":"N\u00a0Engl J Med"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396424004547?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396424004547?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T19:37:49Z","timestamp":1778873869000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396424004547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":66,"alternative-id":["S2352396424004547"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2024.105418","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of Charcot-Leyden Crystal protein on mesothelioma chemotherapy: targeting eosinophils for enhanced chemosensitivity","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2024.105418","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105418"}}